SCHEMBL19687360

SCHEMBL19687360

COc1cc(NC2CCC3(CC2)CC3)nc(-c2nc(C)cs2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 6/20 0.36
ADORA2A P29274 3/20 0.34
PDGFRB P09619 4/20 0.32
PDGFRA P16234 4/20 0.32
TDP1 Q9NUW8 2/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
FABP4 P15090 1/20 0.32
FABP5 Q01469 1/20 0.32
TYK2 P29597 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP1A2 P05177 1/20 0.31
ADORA1 P30542 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687422 0.92 FABP4 (0.34) IDH1ADORA2AFABP4FABP5TYK2
SCHEMBL21143995 0.91 IDH1 (0.36) IDH1ADORA2APDGFRBPDGFRATDP1
SCHEMBL31127167 0.91 IDH1 (0.36) IDH1ADORA2APDGFRBPDGFRATDP1
SCHEMBL19686927 0.90 IDH1 (0.47) IDH1ADORA2AFABP4FABP5IDH2
SCHEMBL21165930 0.89 PDGFRB (0.41) PDGFRBPDGFRATDP1MEN1LMNA
SCHEMBL21165950 0.89 PDGFRB (0.39) ADORA2APDGFRBPDGFRATDP1MEN1
SCHEMBL21165967 0.87 LMNA (0.43) PDGFRBPDGFRATDP1MEN1LMNA
SCHEMBL19686438 0.86 ADORA2A (0.33) IDH1ADORA2APDGFRBPDGFRATDP1
SCHEMBL21165947 0.86 IDH1 (0.47) IDH1ADORA2AIDH2
SCHEMBL21165976 0.85 PDGFRB (0.33) IDH1ADORA2APDGFRBPDGFRATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885ADORA2A 1711/4885PDGFRB 3314/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885ADORA2A 1711/4885PDGFRB 3314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.